Michael J. Kaplan

Clinical Focus

• Cancer > Head and Neck Cancer
• Head and Neck Cancers
• Head and Neck Cancers - Head and Neck Surgery
• Skull Base Tumors
• Salivary Gland Tumors

Administrative Appointments

• Chief, Head & Neck Surgery, Otolaryngology-Head&Neck Surgery (2003 - present)
• Head & Neck Fellowship Director, Otolaryngology-Head&Neck Surgery (2003 - present)

Honors and Awards

• Best Doctors in America, . (1998-2006)
• Chief Residents' Special Certificate of Merit, UCSF (1993)
• Roger Boles Teaching award, UCSF (1987)
• Phi Beta Kappa, Harvard College (1973)

Professional Education

Graduate & Fellowship Program Affiliations

• Cancer Biology
• Neurosciences
• Neurosurgery

Community & International Work

• Institutional Review Board, Stanford, Stanford 
• Ethic Committee 
• Mill Valley Schools Configuration Task Forc, Mill Valley 

Research Interests

1) New therapeutic approaches for head and neck cancer, including immune stimulation possibilities (IRX-2 protocol), integration of biological modifiers, and, eventually, genetic approaches.
2) Head and neck cancer stem cells: identification, characterization, control--in conjunction with the Irv Weissman and Michael Clarke labs in the Stem Cell Institute
3) Development of innovative surgical methods at the anterior cranial base

Clinical Trials

• Biopsy of human tumors for cancer stem cell characterization: a feasibility study Recruiting
• Identification and Characterization of Novel Proteins in Head and Neck Cancer Recruiting
• Phase II Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy Recruiting
• A Phase 2 Clinical Trial of the Effectiveness of IRX-2 in Treating Patients With Operable Head and Neck Cancer No longer recruiting
• Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation No longer recruiting

Publications

• Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Hara W, Loo BW, Goffinet DR, Chang SD, Adler JR, Pinto HA, Fee WE, Kaplan MJ, Fischbein NJ, Le QT. Int J Radiat Oncol Biol Phys. 2008; 71 (2): 393-400
• Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Daly ME, Lieskovsky Y, Pawlicki T, Yau J, Pinto H, Kaplan M, Fee WE, Koong A, Goffinet DR, Xing L, Le QT. Head Neck. 2007; 29 (3): 211-20
• Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. Quon A, Fischbein NJ, McDougall IR, Le QT, Loo BW, Pinto H, Kaplan MJ. J Nucl Med. 2007: 48 Suppl 1 58S-67S
• Plasma osteopontin is an independent prognostic marker for head and neck cancers. Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC, Giaccia AJ, Le QT. J Clin Oncol. 2006; 24 (33): 5291-7
• Advanced-staged tonsillar squamous carcinoma: organ preservation versus surgical management of the primary site. Shirazi HA, Sivanandan R, Goode R, Fee WE, Kaplan MJ, Pinto HA, Goffinet DR, Le QT. Head Neck. 2006; 28 (7): 587-94